Frequency of motor complications in those receiving levodopa in trials of initial treatment for Parkinson’s disease. Presented in order of increasing length of follow up
| Reference | Number | Mean age (y) | Mean duration of PD (y) | Previous levodopa exposure | Mean length of follow up (y) | Mean levodopa daily dose at end of follow up (mg) | Percentage with dyskinesias | Percentage with fluctuations |
|---|---|---|---|---|---|---|---|---|
| PD, Parkinson’s disease; NS, not stated; NA, not assessed. *Estimated from figure in paper. | ||||||||
| Parkinson Study Group, 19964 | 170 | 61.8 | NS | None | 1.7 | 350 | 26 | 48 |
| Parkinson Study Group, 20005 | 150 | 60.9 | 1.8 | 30 subjects, duration not stated | 2 | 509 | 31 | 38 |
| Larsen et al, 19976 | 81 | 64.3 | 2.0 | 22 subjects, 2.7 months | 2.7 | 450 | NA | 27 |
| Caraceni et al, 20017 | 156 | 63.4 | 1.3 | 13 subjects, <4 months | 2.8 | NS | 27 | 30 |
| Rinne et al, 19988 | 204 | 62.6 | 2.0 | None | 3.7 | NS | 14 | 19 |
| Montastruc et al, 19949 | 29 | 62 | 2.7 | None | 4.9 | 569 | 90 (combined dyskinesias and fluctuations) | |
| Dupont et al, 199610 | 29 (completed 5 years) | 66 | 2.7 | None | 5 | 719 | 41 | 59 |
| Koller et al, 199911 | 187 (completed 5 years) | 62 | 2.3 | None | 5 | 426 | 8 | 25* by diary |
| Rascol et al, 200012 | 89 (completed 5 years) | 63 | 2.4 | 7 subjects, <6 weeks | 5 | 753 | 40 | 34 |
| Lees et al, 199513 | 249 | 62.7 | 1.1 | None | 5.5 | 625 at 4 years | 32 | 43 |